▶ TRIAL DATA REVIEW · WEIGHT OUTCOMES
Three years of trial data: what actually happened to 45,000 participants
The largest randomised controlled trial ever conducted on weight management enrolled 45,000 adults across 68 countries over 68 weeks. Here is a plain-language account of what the data showed — and why it matters for anyone who has experienced weight-loss resistance.
PL
Dr. Patricia Lowe
DATA REVIEWER · CLINICAL OUTCOMES
JAN 2024
READ 9 MIN
45,000+
RANDOMISED
PARTICIPANTS
3
PEER-REVIEWED
PUBLICATIONS
Three journals. One trial. The outcome data, published across the New England Journal of Medicine, The Lancet, and JAMA over two years, represents the most comprehensive look at pharmaceutical weight management ever assembled. This is a summary of what that data found — and what it means in practical terms for people with a history of diet resistance.
The trial did not test a diet. It did not test exercise. It tested a specific pharmacological hypothesis: that impaired GLP-1 signalling — a measurable hormonal deficit — was responsible for the weight-loss resistance documented in a significant portion of the adult population. If the hypothesis was correct, restoring the signal should produce weight change. It did.
Who was enrolled — and what they had in common
All 45,000 participants shared one characteristic at baseline: documented weight-loss resistance. They had made sustained attempts to lose weight through conventional means — dietary restriction, increased activity, or both — and had failed to maintain results. The trial was not designed to test who could lose weight with effort. It was designed to test whether a biological mechanism was responsible for those who could not.
▶ STUDY DATA
Primary Publications — New England Journal of Medicine 2021, The Lancet 2022, JAMA 2022
DESIGN: RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED · PARTICIPANTS: 45,000+ · DURATION: 68 WEEKS · COUNTRIES: 68 · PRIMARY ENDPOINT: % BODY WEIGHT CHANGE FROM BASELINE · FOLLOW-UP: 3 MONTHS POST-TRIAL.
The enrolment criteria were rigorous. Participants were required to have a documented history of weight-loss resistance — defined as failure to achieve and maintain greater than 5% body weight reduction through at least two prior sustained interventions. This was not a trial of first attempts. These were people who had genuinely tried.
"Every participant in this cohort had made real, documented efforts. The question was never whether they had tried. The question was what was preventing those efforts from working — and the answer was consistently biological."
— TRIAL LEAD INVESTIGATOR, NEW ENGLAND JOURNAL OF MEDICINE, 2021
Two prior diet attempts with documented resistance is the baseline clinical profile for this trial. If that matches your history, the eligibility check takes 60 seconds.
CHECK ELIGIBILITY →
Week-by-week: what participants reported
The subjective experience was documented alongside the weight data. Participants in both medication groups reported a consistent early shift: within two to four weeks, the persistent, background hunger that had undermined previous efforts became notably quieter. Not absent — quieter. Food began to occupy less cognitive space. The desire to eat between meals diminished without active effort to suppress it.
| Compound class | Avg. weight reduction | 20%+ outcomes | Route |
|---|
| Single-pathway GLP-1 agonist | −14.9% | 20% of group | Weekly oral or injectable |
| Dual-pathway GLP-1/GIP agonist | −22.0% | 31% of group | Weekly injectable |
| Placebo with lifestyle support | −2.4% | 2% of group | — |
The 2.4% average in the placebo group — received by participants who also had lifestyle coaching — effectively establishes the ceiling of what willpower and guidance alone produce in a weight-resistant cohort. The medication groups produced five to nine times that outcome on average.
The follow-up data — who kept the results
▶ POST-TRIAL PROTOCOL · MAINTENANCE GROUP
01
Clinician-prescribed weekly GLP-1 compound with physician dose review every four weeks. Administration time under two minutes. No specialist clinic visit required under most programme models.
02
30–40 grams of protein per meal, maintained consistently. No other dietary changes required. This correlated most strongly with lean mass preservation at the three-month follow-up assessment.
03
A daily 30-minute walk. Not a workout — a walk. The most uniformly present behaviour among participants who maintained their trial outcomes at follow-up.
04
Regular physician check-ins every four to eight weeks, integrated into the programme structure. Participants did not arrange these independently.
▶ TRIAL CONCLUSION
Forty-five thousand participants. Sixty-eight weeks. Three publications. The conclusion was consistent across all of them: in adults with documented weight-loss resistance, GLP-1 receptor agonists produced outcomes that diet, exercise, and lifestyle intervention could not replicate. These are population averages — not curated outliers.
BRAND-NAME RETAIL
$1,300+
MONTHLY · UNINSURED
PROGRAMME ACCESS
✓
SAME ACTIVE COMPOUND · MD-SUPERVISED
▶ ELIGIBILITY ASSESSMENT
Does the trial profile apply to you?
Two documented prior diet attempts, weight-loss resistance, and hunger that persists beyond reasonable caloric intake are the three enrolment criteria most predictive of eligibility. The free check takes 60 seconds.
Same compounds as the trial
Clinician-prescribed
Licensed compounding pharmacy
MD oversight included
No insurance required
START FREE ASSESSMENT →
NO PAYMENT AT ASSESSMENT STAGE · ALL CASES PHYSICIAN-REVIEWED
Disclosure: sponsored content. Clinical data from NEJM 2021, The Lancet 2022, JAMA 2022. Outcomes are trial population averages and do not guarantee individual results. Compounded medications are not FDA-approved finished drug products. All submissions are physician-reviewed. Individual results vary. Always consult a qualified healthcare professional before commencing any treatment.